| Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence CR Fumaz, JA Munoz-Moreno, J Moltó, E Negredo, MJ Ferrer, G Sirera, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 38 (5), 560-565, 2005 | 211 | 2005 |
| Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients … E Negredo, M Massanella, J Puig, N Pérez-Alvarez, JM Gallego-Escuredo, ... Clinical infectious diseases 50 (9), 1300-1308, 2010 | 173 | 2010 |
| Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load E Negredo, J Moltó, D Burger, P Viciana, E Ribera, R Paredes, M Juan, ... Aids 18 (3), 459-463, 2004 | 156 | 2004 |
| Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients JA Muñoz-Moreno, CR Fumaz, MJ Ferrer, A Prats, E Negredo, M Garolera, ... AIDS research and human retroviruses 24 (10), 1301-1307, 2008 | 142 | 2008 |
| Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients A Pruvost, E Negredo, H Benech, F Theodoro, J Puig, E Grau, E García, ... Antimicrobial agents and chemotherapy 49 (5), 1907-1914, 2005 | 128 | 2005 |
| Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review JA Munoz-Moreno, CR Fumaz, MJ Ferrer, M González-García, J Moltó, ... Aids Rev 11 (2), 103-9, 2009 | 108 | 2009 |
| Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins E Negredo, J Molto, J Puig, D Cinquegrana, A Bonjoch, N Perez-Alvarez, ... Aids 20 (17), 2159-2164, 2006 | 99 | 2006 |
| The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women APH Colbers, DA Hawkins, A Gingelmaier, K Kabeya, JK Rockstroh, ... Aids 27 (5), 739-748, 2013 | 96 | 2013 |
| Determinants of virological failure and antiretroviral drug resistance in Mozambique M Rupérez, C Pou, S Maculuve, S Cedeno, L Luis, J Rodríguez, E Letang, ... Journal of Antimicrobial Chemotherapy 70 (9), 2639-2647, 2015 | 89 | 2015 |
| Aging in HIV‐infected subjects: a new scenario and a new view E Negredo, D Back, JR Blanco, J Blanco, KM Erlandson, M Garolera, ... BioMed research international 2017 (1), 5897298, 2017 | 87 | 2017 |
| HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02) B Mothe, M Rosás-Umbert, P Coll, C Manzardo, MC Puertas, ... Frontiers in immunology 11, 823, 2020 | 84 | 2020 |
| Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz JM Llibre, JR Santos, T Puig, J Molto, L Ruiz, R Paredes, B Clotet Journal of Antimicrobial Chemotherapy 62 (5), 909-913, 2008 | 77 | 2008 |
| Raltegravir in HIV-1–Infected pregnant women: pharmacokinetics, safety, and efficacy MI Blonk, APH Colbers, C Hidalgo-Tenorio, K Kabeya, K Weizsäcker, ... Clinical infectious diseases 61 (5), 809-816, 2015 | 71 | 2015 |
| Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus–infected homosexual man S Franco, C Tural, M Nevot, J Moltó, JK Rockstroh, B Clotet, MA Martinez Gastroenterology 147 (3), 599-601. e1, 2014 | 66 | 2014 |
| Resilience, ageing, and quality of life in long-term diagnosed HIV-infected patients CR Fumaz, A Ayestaran, N Perez-Alvarez, JA Muñoz-Moreno, J Moltó, ... Aids Care 27 (11), 1396-1403, 2015 | 62 | 2015 |
| Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach E Negredo, J Moltó, JA Muñoz-Moreno, E Pedrol, E Ribera, P Viciana, ... Antiviral therapy 9 (3), 335-342, 2004 | 61 | 2004 |
| Herb-Drug Interaction between Echinacea purpurea and Darunavir-Ritonavir in HIV-Infected Patients J Moltó, M Valle, C Miranda, S Cedeno, E Negredo, MJ Barbanoj, B Clotet Antimicrobial agents and chemotherapy 55 (1), 326-330, 2011 | 58 | 2011 |
| Variability in non‐nucleoside reverse transcriptase and protease inhibitors concentrations among HIV‐infected adults in routine clinical practice J Moltó, A Blanco, C Miranda, J Miranda, J Puig, M Valle, M DelaVarga, ... British journal of clinical pharmacology 63 (6), 715-721, 2007 | 58 | 2007 |
| Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women A Colbers, J Moltó, J Ivanovic, K Kabeya, D Hawkins, A Gingelmaier, ... Journal of antimicrobial chemotherapy 70 (2), 534-542, 2015 | 56 | 2015 |
| Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults J Moltó, MJ Barbanoj, C Miranda, A Blanco, JR Santos, E Negredo, ... Clinical pharmacokinetics 47, 681-692, 2008 | 51 | 2008 |
